Teva wins FDA approval for monthly schizophrenia injection Weltruza
09/10/2026 12:16
Teva wins FDA approval for monthly schizophrenia injection Weltruza Oct 9 (Reuters) - Teva TEVA.TA said on Friday it had received approval from the US Food and Drug Administration for its Weltruza drug for extended-release injectable suspension as the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.
Israel-based Teva, which is leading the development and commercialisation of the treatment under its partnership with France's Medincell MEDCL.PA, said it expected to launch the product in the US in the coming weeks.
(Reporting by Lucie Barbier in Gdansk, editing by Milla Nissi-Prussak)
((Email: lucie.barbier@thomsonreuters.com))
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris